MedTrace Logo

Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)

NCT03918148 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1150

Last updated 2024-04-19

No results posted yet for this study

Summary

GIOIA represents a multicenter pragmatic prospective cohort study, aimed at evaluating the effects of SGLT2 inhibitors currently marketed (dapagliflozin, canagliflozin, empagliflozin) on markers of vascular, myocardial and renal damage, in patients with type 2 diabetes not well controlled with metformin and/or basal insulin. The changes of the interest outcomes are compared with those obtained with a comparator glucose lowering class (DPP-4inhibitors) over a follow-up of two years.

Conditions

Interventions

DRUG

SGLT-2i

Dapagliflozin or canagliflozin or empagliflozin add on to metformin ± basal insulin

DRUG

DPP-4i

Sitagliptin or vildagliptin or saxagliptin or linagliptin or alogliptin add on to metformin ± basal insulin

Sponsors & Collaborators

  • University of Campania Luigi Vanvitelli

    lead OTHER

Principal Investigators

  • Katherine Esposito · University of Campania Luigi Vanvitelli

  • Dario Giugliano · University of Campania Luigi Vanvitelli

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-15
Primary Completion
2023-12-31
Completion
2023-12-31
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03918148 on ClinicalTrials.gov